Stock SUS SURGICAL SCIENCE SWEDEN AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Surgical Science Sweden AB

Equities

SUS

SE0014428512

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm
Other stock markets
 08:59:46 26/04/2024 pm IST 		5-day change 1st Jan Change
148.8 SEK +5.38% Intraday chart for Surgical Science Sweden AB +2.83% -18.47%
15/04 Gisli Hennermark to Leave His Position as CEO of Surgical Science Sweden AB CI
12/03 Surgical Science Sweden to Step Down; Search for Successor Starts MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,851 3,225 14,301 8,367 9,312 7,593 - -
Enterprise Value (EV) 1 2,782 3,138 13,984 8,367 9,312 6,730 6,459 6,019
P/E ratio 195 x 208 x 139 x 44.6 x 39.8 x 35.7 x 25 x 17.3 x
Yield - - - - - - - 0.22%
Capitalization / Revenue 28.1 x 30.8 x 39 x 10.4 x 10.5 x 7.6 x 6.34 x 5.24 x
EV / Revenue 27.4 x 29.9 x 38.1 x 10.4 x 10.5 x 6.73 x 5.39 x 4.15 x
EV / EBITDA 91.6 x 84.8 x 118 x 39.1 x 38 x 21.6 x 14.6 x 9.96 x
EV / FCF 50.7 x 216 x 566 x - - 30.8 x 21.5 x 13 x
FCF Yield 1.97% 0.46% 0.18% - - 3.25% 4.65% 7.7%
Price to Book 7.1 x 7.55 x 3.99 x - - 1.65 x 1.54 x 1.42 x
Nbr of stocks (in thousands) 33,622 34,495 50,801 50,801 51,026 51,026 - -
Reference price 2 84.80 93.50 281.5 164.7 182.5 148.8 148.8 148.8
Announcement Date 07/02/20 11/02/21 16/02/22 22/02/23 21/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 101.5 104.8 366.8 802.5 882.9 999.4 1,197 1,449
EBITDA 1 30.36 37 118.5 214.1 244.8 312.3 442.7 604.3
EBIT 1 15.18 19.97 85 162.5 189.2 255.8 377.9 542
Operating Margin 14.95% 19.06% 23.17% 20.25% 21.43% 25.59% 31.56% 37.4%
Earnings before Tax (EBT) 1 15.25 19.66 65.8 208.2 268.3 265.6 382.7 553.6
Net income 1 12.6 15.61 86.25 188 234 212.1 303.8 436.8
Net margin 12.41% 14.89% 23.52% 23.42% 26.5% 21.22% 25.37% 30.14%
EPS 2 0.4340 0.4500 2.020 3.690 4.590 4.166 5.961 8.580
Free Cash Flow 1 54.88 14.53 24.71 - - 218.7 300.6 463.3
FCF margin 54.06% 13.87% 6.74% - - 21.88% 25.1% 31.97%
FCF Conversion (EBITDA) 180.73% 39.27% 20.85% - - 70.02% 67.9% 76.67%
FCF Conversion (Net income) 435.62% 93.11% 28.65% - - 103.1% 98.93% 106.07%
Dividend per Share 2 - - - - - - - 0.3333
Announcement Date 07/02/20 11/02/21 16/02/22 22/02/23 21/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 95.32 197.7 159.1 188.2 205.1 250.1 229.1 216.2 210.2 227.3 228 244.2 248.8 282.2 265
EBITDA 1 36.5 60.41 32.4 51.1 55.8 74.9 66.8 61.3 64.9 51.8 65.21 72.1 75.68 99.59 91
EBIT 1 29.4 45.13 25.5 38.59 42.71 61.22 53.27 47.54 50.69 37.7 51.31 58.3 61.87 86.47 77
Operating Margin 30.84% 22.83% 16.02% 20.5% 20.83% 24.48% 23.25% 21.98% 24.11% 16.59% 22.5% 23.87% 24.87% 30.63% 29.06%
Earnings before Tax (EBT) 1 2.872 60.43 17.9 29.6 33.68 127 55.03 42.36 52.43 118.4 55.66 63.15 65.67 85.18 77
Net income 1 14.37 66.89 16.48 26.47 28.5 116.5 49.82 38.79 47.4 98 41.92 47.6 50.68 70.11 61
Net margin 15.07% 33.84% 10.36% 14.06% 13.9% 46.59% 21.75% 17.94% 22.55% 43.12% 18.39% 19.49% 20.37% 24.84% 23.02%
EPS 2 0.3200 1.310 0.3200 0.5200 0.5600 2.290 0.9800 0.7600 0.9300 1.920 0.8218 0.9346 0.9923 1.366 1.200
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/11/21 16/02/22 11/05/22 25/08/22 10/11/22 22/02/23 16/05/23 24/08/23 09/11/23 21/02/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 69.2 87.2 317 - - 863 1,134 1,574
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 54.9 14.5 24.7 - - 219 301 463
ROE (net income / shareholders' equity) 5.24% 3.77% 4.3% - - 4.62% 6.2% 8.55%
ROA (Net income/ Total Assets) - - - - - 4.1% 5.8% 7.1%
Assets 1 - - - - - 5,173 5,238 6,152
Book Value Per Share 2 11.90 12.40 70.60 - - 90.00 96.80 105.0
Cash Flow per Share 2 - 0.6800 0.9200 - - 3.910 6.150 7.680
Capex 1 202 8.69 14.4 - - 51.9 61.1 52.2
Capex / Sales 198.7% 8.3% 3.92% - - 5.19% 5.1% 3.6%
Announcement Date 07/02/20 11/02/21 16/02/22 22/02/23 21/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Surgical Science Sweden AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
148.8 SEK
Average target price
221.5 SEK
Spread / Average Target
+48.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
SURGICAL SCIENCE SWEDEN AB Stock Surgical Science Sweden AB
-18.47% 693M
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
SECTRA AB Stock Sectra AB
+22.93% 3.89B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.17B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. SUS Stock
  4. Financials Surgical Science Sweden AB